PharmaCyte Biotech, Inc. (PMCB): Total Assets
$46.75M
As of 2026-04-30
$36.71M
As of 2026-07-31
-13.9%
3-year compound annual growth
+44.6%
5-year compound annual growth
+20.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $46.75M | -15.3% | 2026-07-29, Balance as of period end |
| 2025-04-30 | $55.17M | -7.9% | 2026-07-29, Balance as of period end |
| 2024-04-30 | $59.90M | -18.3% | 2025-08-11, Balance as of period end |
| 2023-04-30 | $73.28M | -19.1% | 2024-08-13, Balance as of period end |
| 2022-04-30 | $90.62M | n/m | 2023-07-31, Balance as of period end |
| 2021-04-30 | $7.40M | +20.1% | 2022-07-28, Balance as of period end |
| 2020-04-30 | $6.17M | +6.6% | 2021-08-10, Balance as of period end |
| 2019-04-30 | $5.78M | -9.8% | 2020-08-13, Balance as of period end |
| 2018-04-30 | $6.41M | -26.0% | 2019-08-13, Balance as of period end |
| 2017-04-30 | $8.67M | +21.0% | 2018-07-20, Balance as of period end |
| 2016-04-30 | $7.16M | -23.0% | 2017-07-27, Balance as of period end |
| 2015-04-30 | $9.30M | -0.2% | 2016-07-29, Balance as of period end |
| 2014-04-30 | $9.32M | +223.8% | 2016-01-19, Balance as of period end |
| 2013-04-30 | $2.88M | +37.8% | 2014-08-04, Balance as of period end |
| 2012-04-30 | $2.09M | +68.3% | 2013-07-29, Balance as of period end |
| 2011-04-30 | $1.24M | n/a | 2012-08-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $46.75M | -15.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
Compare PMCB, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗